不寧腿症候群(RLS)治療藥物市場 ;開發平台分析及市場預測 是由出版商GlobalData在2011年08月所出版的。
這份英文市場調查報告書包含Pages: 67 價格從美金2000起跳。
本報告提供全球不寧腿症候群治療藥物市場相關的開發平台分析及市場預測，以市場特徵為首，評估分析競爭，開發平台等，再加入未來市場競爭、企業簡介等資料，為您概述為以下內容。
1 目錄 1 目錄 2 不寧腿症候群治療藥物 - 簡介
- 2.1 疾病 概要
- 2.1.1 原發性 RLS
- 2.1.2 次發性 RLS
- 2.2 免疫學
- 2.3 病因及病理學
- 2.4 徵兆及症狀
- 2.5 診斷
- 2.6 治療及管理選擇
- 2.6.1 非藥物療法
- 2.6.2 藥物療法
- 2.6.3 治療模式;原發性 RLS
- 2.6.4 治療方法; 次發性 RLS
- 2.6.5 其他 醫藥品
- 2.7 GlobalData 開發平台報告指南
3 RLS 治療藥物 - 市場特性
- 3.1 概要
- 3.2 RLS 治療藥物市場規模 - 全球
- 3.3 RLS 治療藥物市場預測 - 全球
- 3.4 RLS 治療藥物市場規模 - 美國
- 3.5 RLS 治療藥物市場預測 - 美國
- 3.6 RLS 治療藥物市場規模 - 法國
- 3.7 RLS 治療藥物市場預測 - 法國
- 3.8 RLS 治療藥物市場規模 - 德國
- 3.9 RLS 治療藥物市場預測 - 德國
- 3.10 RLS 治療藥物市場規模 - 義大利
- 3.11 RLS 治療藥物市場預測 - 義大利
- 3.12 RLS 治療藥物市場規模 - 西班牙
- 3.13 RLS 治療藥物市場預測 - 西班牙
- 3.14 RLS 治療藥物市場規模 - 英國
- 3.15 RLS 治療藥物市場預測 - 英國
- 3.16 RLS 治療藥物市場規模 - 日本
- 3.17 RLS 治療藥物市場預測 - 日本
- 3.18 推動力與障礙;RLS 治療藥物市場
- 3.18.1 推動力; RLS 治療藥物市場
- 3.18.2 障礙; RLS 治療藥物市場
- 3.19 機會及未飽合需求分析
- 3.20 要點
4 RLS 治療藥物 - 競爭評估
- 4.1 概要
- 4.2 策略性競爭對手評估
- 4.3 主要上市產品簡介 - RLS 治療藥物市場
- 4.3.1 Requip (ropinirole)
- 4.3.2 Mirapex (pramipexole)
- 4.3.3 Horizant (gabapentin enacarbil)
- 4.3.4 Neupro (rotigotine)
- 4.4 要點
5 RLS 治療藥物 - 開發平台評估
- 5.1 概要
- 5.2 策略性開發平台評估
- 5.3 RLS 治療藥物 開發平台 - 各開發階段平台
- 5.3.1 RLS 治療藥物 - 申請許可中的產品
- 5.3.2 RLS 治療藥物 - 第三階段平台
- 5.3.3 RLS 治療藥物 - 第二階段平台
- 5.3.4 RLS 市場 - 發現階段及臨床前平台
- 5.3.5 技術趨勢的分析結構
- 5.4 RLS 治療藥物市場 - 各作用機制平台
- 5.5 RLS 治療藥物 - 正在開發的潛力治療藥物
- 5.6 簡介; 潛力治療藥物
- 5.7 要點
6 RLS 治療藥物 - 臨床實驗藍圖
- 6.1 臨床實驗 各區各國 (The 美國、歐盟五國、日本)
- 6.2 臨床實驗 各階段
- 6.3 臨床實驗 各臨床實驗狀態
- 6.4 有力的贊助商
- 6.5 前幾名參與企業 - RLS 治療藥物的臨床實驗
7 策略性評估
- 7.1 影響未來市場的主要事件
- 7.2 RLS 治療藥物 - 對於未來市場競爭的建議
8 RLS 治療藥物 - 有未來潛力的企業
- 8.1 簡介
- 8.2 企業簡介
- 8.2.1 GlaxoSmithKline Plc.
- 8.2.2 UCB .S.A.
- 8.2.3 Boehringer Ingelheim GmbH
9 RLS 治療藥物 - 授權合約及合作交易 10 RLS 治療藥物 - 附錄
- 10.1 市場定義
- 10.2 簡稱
- 10.3 調查方法
- 10.3.1 調查範圍
- 10.3.2 二級研究
- 10.3.3 預測
- 10.3.4 主要研究
- 10.3.5 專門委員會驗證
- 10.4 諮詢方式
- 10.5 免責聲明
- 10.6 參考文獻
1.1 表格一覽
- 表格 1: RLS 全球治療藥物市場, 收益 ($m)
- 表格 2: RLS 全球治療藥物市場，預測 ($m)
- 表格 3: RLS 治療藥物市場, 美國, 收益 ($m)
- 表格 4: RLS 治療藥物市場, 美國，預測 ($m)
- 表格 5: RLS 治療藥物市場, 法國, 收益 ($m)
- 表格 6: RLS 治療藥物市場, 法國，預測 ($m)
- 表格 7: RLS 治療藥物市場, 德國, 收益 ($m)
- 表格 8: RLS 治療藥物市場, 德國，預測 ($m)
- 表格 9: RLS 治療藥物市場, 義大利, 收益 ($m)
- 表格 10: RLS 治療藥物市場, 義大利，預測 ($m)
- 表格 11: RLS 治療藥物市場, 西班牙, 收益 ($m)
- 表格 12: RLS 治療藥物市場, 西班牙，預測 ($m)
- 表格 13: RLS 治療藥物市場, 英國, 收益 ($m)
- 表格 14: RLS 治療藥物市場, 英國，預測 ($m)
- 表格 15: RLS 治療藥物市場, 日本, 收益 ($m)
- 表格 16: RLS 治療藥物市場, 日本，預測 ($m)
- 表格 17: IRLS 評分的平均的變化及反應者的比例(CGI-I)
- 表格 18: IRLS規模的平均的變化/第12週的 CGI-I 規模的總評分及反應者的比例
- 表格 19: 反應者分析;CGI Item 1 (SP790及SP792)
- 表格 20: RLS 治療藥物 - 申請許可中的產品
- 表格 21: RLS 治療藥物 - 第三階段平台
- 表格 22: RLS 治療藥物 - 第二階段平台
- 表格 23: RLS 治療藥物 - 發現階段及臨床前平台
- 表格 24: RLS 治療藥物 - 臨床實驗 各國
- 表格 25: RLS 治療藥物 - 臨床實驗 各階段
- 表格 26: RLS 治療藥物 - 臨床實驗 不同狀況
- 表格 27: RLS 治療藥物 - 有力的贊助商
- 表格 28: RLS 治療藥物 - 前幾名參與企業 - 治療藥物的臨床實驗
- 表格 29: GlaxoSmithKline Plc. - CNS 開發平台
- 表格 30: GlaxoSmithKline Plc. 交易概要, 合作及夥伴關係
- 表格 31: UCB S．A. - CNS 開發平台
- 表格 32: UCB S．A. 交易概要, 合作及夥伴關係
- 表格 33: Boehringer Ingelheim GmbH - 交易概要
- 表格 34: RLS 治療藥物, 全球, 交易概要
1.2 圖表一覽
- 圖 1: 病因論;RLS
- 圖 2: 治療模式;原發性 RLS
- 圖 3: 詢問途徑;RLS
- 圖 4: RLS 全球治療藥物市場, 收益 ($m)
- 圖 5: RLS 全球治療藥物市場，預測 ($m)
- 圖 6: RLS 治療藥物市場, 美國, 收益 ($m)
- 圖 7: RLS 治療藥物市場, 美國，預測 ($m)
- 圖 8: RLS 治療藥物市場, 法國, 收益 ($m)
- 圖 9: RLS 治療藥物市場, 法國，預測 ($m)
- 圖 10: RLS 治療藥物市場, 德國, 收益 ($m)
- 圖 11: RLS 治療藥物市場, 德國，預測 ($m)
- 圖 12: RLS 治療藥物市場, 義大利, 收益 ($m)
- 圖 13: RLS 治療藥物市場, 義大利，預測 ($m)
- 圖 14: RLS 治療藥物市場, 西班牙, 收益 ($m)
- 圖 15: RLS 治療藥物市場, 西班牙，預測 ($m)
- 圖 16: RLS 治療藥物市場, 英國, 收益 ($m)
- 圖 17: RLS 治療藥物市場, 英國，預測 ($m)
- 圖 18: RLS 治療藥物市場, 日本, 收益 ($m)
- 圖 19: RLS 治療藥物市場, 日本，預測 ($m)
- 圖 20: 機會及未飽和需求 - RLS 治療藥物市場
- 圖 21: RLS 治療藥物 - 策略性競爭對手評估
- 圖 22: RLS 治療藥物 - 各開發階段平台
- 圖 23: RLS 治療藥物 - 技術趨勢的分析結構
- 圖 24: RLS 治療藥物 - 技術趨勢的分析結構 - 插圖說明
- 圖 25: RLS 治療藥物 - 各作用機制平台
- 圖 26: 臨床實驗 詳細內容資訊; Rasagiline
- 圖 27: RLS 治療藥物 - 臨床實驗 各國
- 圖 28: RLS 治療藥物 - 臨床實驗 各階段
- 圖 29: RLS 治療藥物 - 臨床實驗 不同狀況
- 圖 30: RLS 治療藥物 - 贊助商整體
- 圖 31: RLS 治療藥物 - 有力的贊助商
- 圖 32: RLS 治療藥物 - 前幾名參與企業 - 治療藥物的臨床實驗
- 圖 33: RLS 治療藥物市場, 推動力及抑制力
- 圖 34: 對於未來市場競爭的建議 - RLS 市場
- 圖 35: RLS 治療藥物市場 - 各開發平台企業
Abstract
Restless Leg Syndrome (RLS) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData, the industry analysis specialist, has released its new report, "Restless Leg Syndrome (RLS) Therapeutics - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global therapeutics market. The report identifies the key trends shaping and driving the global restless leg syndrome therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global restless leg syndrome therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
GlobalData estimates that the Restless Leg Syndrome Therapeutics (RLS) market was valued at $360m in 2010, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 11.4% over the next seven years, to reach $766m by 2017.
Scope
The report provides information on the key drivers and challenges of the RLS market. Its scope includes -
- Annualized global RLS market revenues data from 2005 to 2010, forecast for seven years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as dopamine agonists, dopamine partial agonist, Monoamine Oxidase (MAO) inhibitors, phosphodiesterase inhibitors and neuromuscular transmission inhibitors
- Analysis of the current and future competition in the global RLS therapeutics market. Key market players covered are UCB S.A., Otsuka Pharmaceuticals, GSK and Boehringer Ingelheim GmbH.Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the RLS therapeutics market.
- Analysis of key recent licensing and partnership agreements in RLS therapeutics market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global RLS therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global RLS therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global RLS therapeutics market landscape? - Identify, understand and capitalize.
1 Table of contents
1 Table of contents 2
- 1.1 List of Tables 4
- 1.2 List of Figures 5
2 Restless Leg Syndrome Therapeutics - Introduction 6
- 2.1 Disease Overview 6
- 2.1.1 Primary RLS 6
- 2.1.2 Secondary RLS 6
- 2.2 Epidemiology 6
- 2.3 Etiology and Pathophysiology 7
- 2.4 Signs and Symptoms 8
- 2.5 Diagnosis 8
- 2.6 Treatment and Management Options 9
- 2.6.1 Non-Pharmacological Treatment 9
- 2.6.2 Pharmacological Treatment 9
- 2.6.3 Treatment Pattern of Primary RLS 10
- 2.6.4 Treatment for Secondary RLS 10
- 2.6.5 Other Medications 10
- 2.7 GlobalData Pipeline Report Guidance 12
3 RLS Therapeutics - Market Characterization 13
- 3.1 Overview 13
- 3.2 RLS Therapeutics Market Size (2005 - 2010) - Global 13
- 3.3 RLS Therapeutics Market Forecast (2010 - 2017) - Global 14
- 3.4 RLS Therapeutics Market Size (2005 - 2010) - The US 15
- 3.5 RLS Therapeutics Market Forecast (2010 - 2017) - The US 16
- 3.6 RLS Therapeutics Market Size (2005 - 2010) - France 17
- 3.7 RLS Therapeutics Market Forecast (2010 - 2017) - France 18
- 3.8 RLS Therapeutics Market Size (2005 - 2010) - Germany 19
- 3.9 RLS Therapeutics Market Forecast (2010 - 2017) - Germany 20
- 3.10 RLS Therapeutics Market Size (2005 - 2010) - Italy 21
- 3.11 RLS Therapeutics Market Forecast (2010 - 2017) - Italy 22
- 3.12 RLS Therapeutics Market Size (2005 - 2010) - Spain 23
- 3.13 RLS Therapeutics Market Forecast (2010 - 2017) - Spain 24
- 3.14 RLS Therapeutics Market Size (2005 - 2010) - The UK 25
- 3.15 RLS Therapeutics Market Forecast (2010 - 2017) - The UK 26
- 3.16 RLS Therapeutics Market Size (2005 - 2010) - Japan 27
- 3.17 RLS Therapeutics Market Forecast (2010-2017) - Japan 28
- 3.18 Drivers and Barriers of the RLS Therapeutics Market 29
- 3.18.1 Drivers for the RLS Therapeutics Market 29
- 3.18.2 Barriers for the RLS Therapeutics Market 29
- 3.19 Analysis of Opportunity and Unmet Need 30
- 3.20 Key Takeaway 30
4 RLS Therapeutics - Competitive Assessment 31
- 4.1 Overview 31
- 4.2 Strategic Competitor Assessment 31
- 4.3 Product Profiles for the Major Marketed Products in the RLS Therapeutics Market 32
- 4.3.1 Requip (ropinirole) 32
- 4.3.2 Mirapex (pramipexole) 33
- 4.3.3 Horizant (gabapentin enacarbil) 34
- 4.3.4 Neupro (rotigotine) 35
- 4.4 Key Takeaway 37
5 RLS Therapeutics - Pipeline Assessment 38
- 5.1 Overview 38
- 5.2 Strategic Pipeline Assessment 38
- 5.3 RLS Therapeutics Pipeline - Pipeline by Phases of Development 38
- 5.3.1 RLS Therapeutics - Regulatory Filed Products 38
- 5.3.2 RLS Therapeutics - Phase III Pipeline 38
- 5.3.3 RLS Therapeutics - Phase II Pipeline 39
- 5.3.4 RLS Market - Discovery and Pre-Clinical Pipeline 39
- 5.3.5 Technology Trends Analytic Framework 39
- 5.4 RLS Therapeutics Market - Pipeline by Mechanism of Action 41
- 5.5 RLS Therapeutics - Promising Drugs in Development 42
- 5.6 Profile for Promising Drugs 42
- 5.7 Key Takeaway 42
6 RLS Therapeutics - Clinical Trials Mapping 43
- 6.1 Clinical Trials by Region/Country (The US, EU5 and Japan) 43
- 6.2 Clinical Trials by Phase 44
- 6.3 Clinical Trials by Trial Status 45
- 6.4 Prominent Sponsors 46
- 6.5 Top Companies Participating in RLS Therapeutics Clinical Trials 48
7 Strategic Assessment 49
- 7.1 Key Events Affecting the Future Market 49
- 7.2 RLS Therapeutics - Implications for Future Market Competition 49
8 RLS Therapeutics - Future Players 51
- 8.1 Introduction 51
- 8.2 Company Profiles 51
- 8.2.1 GlaxoSmithKline Plc. 51
- 8.2.2 UCB .S.A. 56
- 8.2.3 Boehringer Ingelheim GmbH 57
9 RLS Therapeutics - Licensing and Partnership Deals 60
10 RLS Therapeutics - Appendix 61
- 10.1 Market Definitions 61
- 10.2 Abbreviations 61
- 10.3 Methodology 62
- 10.3.1 Coverage 62
- 10.3.2 Secondary Research 62
- 10.3.3 Forecasting 63
- 10.3.4 Primary Research 64
- 10.3.5 Expert Panel Validation 64
- 10.4 Contact Us 65
- 10.5 Disclaimer 65
- 10.6 Bibliography 65
1.1 List of Tables
- Table 1: RLS Therapeutics Market, Global, Revenue ($m), 2005 - 2010 13
- Table 2: RLS Therapeutics Market, Global, Forecast ($m), 2010 - 2017 14
- Table 3: RLS Therapeutics Market, The US, Revenue ($m), 2005 - 2010 15
- Table 4: RLS Therapeutics Market, The US, Forecast ($m), 2010 - 2017 16
- Table 5: RLS Therapeutics Market, France, Revenue ($m), 2005 - 2010 17
- Table 6: RLS Therapeutics Market, France, Forecast ($m), 2010 - 2017 18
- Table 7: RLS Therapeutics Market, Germany, Revenue ($m), 2005 - 2010 19
- Table 8: RLS Therapeutics Market, Germany, Forecast ($m), 2010 - 2017 20
- Table 9: RLS Therapeutics Market, Italy, Revenue ($m), 2005 - 2010 21
- Table 10: RLS Therapeutics Market, Italy, Forecast ($m), 2010 - 2017 22
- Table 11: RLS Therapeutics Market, Spain, Revenue ($m), 2005 - 2010 23
- Table 12: RLS Therapeutics Market, Spain, Forecast ($m), 2010 - 2017 24
- Table 13: RLS Therapeutics Market, The UK, Revenue ($m), 2005 - 2010 25
- Table 14: RLS Therapeutics Market, The UK, Forecast ($m), 2010 - 2017 26
- Table 15: RLS Therapeutics Market, Japan, Revenue ($m), 2005 - 2010 27
- Table 16: RLS Therapeutics Market, Japan, Forecast ($m), 2010 - 2017 28
- Table 17: Mean Change in IRLS Score and Percent Responders on CGI-I 32
- Table 18: Mean Change in IRLS Scale Total Score and Proportion of Responders on CGI-I Scale at Week 12 35
- Table 19: Responder analysis of CGI Item 1 in studies SP790 and SP792 36
- Table 20: RLS Therapeutics - Regulatory Filed Products, 2011 38
- Table 21: RLS Therapeutics - Phase III Pipeline, 2011 38
- Table 22: RLS Therapeutics - Phase II Pipeline, 2011 39
- Table 23: RLS Therapeutics - Discovery and Pre-Clinical Pipeline, 2011 39
- Table 24: RLS Therapeutics - Clinical Trials by Country, 2011 43
- Table 25: RLS Therapeutics - Clinical Trials by Phase, 2011 44
- Table 26: RLS Therapeutics - Clinical Trials by Status, 2011 45
- Table 27: RLS Therapeutics - Prominent Sponsors, 2011 47
- Table 28: RLS Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011 48
- Table 29: GlaxoSmithKline Plc. - CNS Pipeline, 2011 52
- Table 30: GlaxoSmithKline Plc. Deals, Alliances and Partnerships , 2010-2011 53
- Table 31: UCB S.A. - CNS Pipeline, 2011 56
- Table 32: UCB S.A. Deals, Alliances and Partnerships , 2010-2011 57
- Table 33: Boehringer Ingelheim GmbH - Deals, 2009-2011 58
- Table 34: RLS Therapeutics, Global, Deals 60
1.2 List of Figures
- Figure 1: Etiology of RLS 7
- Figure 2: Treatment Pattern of Primary RLS 10
- Figure 3: Referral Pathway for RLS 11
- Figure 4: RLS Therapeutics Market, Global, Revenue ($m), 2005 - 2010 13
- Figure 5: RLS Therapeutics Market, Global, Forecast ($m), 2010 - 2017 14
- Figure 6: RLS Therapeutics Market, The US, Revenue ($m), 2005 - 2010 15
- Figure 7: RLS Therapeutics Market, The US, Forecast ($m), 2010 - 2017 16
- Figure 8: RLS Therapeutics Market, France, Revenue ($m), 2005 - 2010 17
- Figure 9: RLS Therapeutics Market, France, Forecast ($m), 2010 - 2017 18
- Figure 10: RLS Therapeutics Market, Germany, Revenue ($m), 2005 - 2010 19
- Figure 11: RLS Therapeutics Market, Germany, Forecast ($m), 2010 - 2017 20
- Figure 12: RLS Therapeutics Market, Italy, Revenue ($m), 2005 - 2010 21
- Figure 13: RLS Therapeutics Market, Italy, Forecast ($m), 2010 - 2017 22
- Figure 14: RLS Therapeutics Market, Spain, Revenue ($m), 2005 - 2010 23
- Figure 15: RLS Therapeutics Market, Spain, Forecast ($m), 2010 - 2017 24
- Figure 16: RLS Therapeutics Market, The UK, Revenue ($m), 2005 - 2010 25
- Figure 17: RLS Therapeutics Market, The UK, Forecast ($m), 2010 - 2017 26
- Figure 18: RLS Therapeutics Market, Japan, Revenue ($m), 2005 - 2010 27
- Figure 19: RLS Therapeutics Market, Japan, Forecast ($m), 2010 - 2017 28
- Figure 20: Opportunity and Unmet Need in the RLS Therapeutics Market, 2010 30
- Figure 21: RLS Therapeutics - Strategic Competitor Assessment, 2011 31
- Figure 22: RLS Therapeutics - Pipeline by Phase of Development, 2011 38
- Figure 23: RLS Therapeutics - Technology Trends Analytics Framework, 2011 39
- Figure 24: RLS Therapeutics - Technology Trends Analytics Framework - Description, 2011 40
- Figure 25: RLS Therapeutics - Pipeline by Mechanism of Action, 2011 41
- Figure 26: Clinical Trial Details of Rasagiline 42
- Figure 27: RLS Therapeutics - Clinical Trials by Country, 2011 43
- Figure 28: RLS Therapeutics - Clinical Trials by Phase, 2011 44
- Figure 29: RLS Therapeutics - Clinical Trials by Status, 2011 45
- Figure 30: RLS Therapeutics - Overall Sponsors, 2011 46
- Figure 31: RLS Therapeutics - Prominent Sponsors, 2011 46
- Figure 32: RLS Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011 48
- Figure 33: RLS Therapeutics Market, Drivers and Restraints, 2011 49
- Figure 34: Implications for Future Market Competition in the RLS Market, 2011 49
- Figure 35: RLS Therapeutics Market - Pipeline by Company, 2011 51
|
